Interleukin-3 may reprogram immune responses in the brain that cause cell death and lead to dementia.
- Young-onset dementia challenges couples to face a rapidly progressive terminal illness with an uncertain future.
- By understanding the lived experiences of couples coping with the condition, researchers identified building blocks for a novel couples-based approach to illness management.
Sarah Bannon, PhD
Our work shows the potential to develop resources that actively involve both partners and teach them skills to increase positive communication and mutual problem-solving.
Integrated Brain Health Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital
BOSTON – Researchers from Massachusetts General Hospital (MGH) have used a couples-based framework to describe the experiences of individuals diagnosed with young-onset dementia (YOD) and their partners. In a study published in JAMA Network Open, the team conducted in-depth interviews to understand how couples navigate challenges related to YOD. This framework has been used to successfully develop patient-caregiver treatments for other severe medical conditions, including stroke, breast cancer and neurological injury. Using this approach to understand couples’ coping patterns within YOD can help increase much-needed resources for affected couples.
Young-onset dementias are defined by their symptom onset before age 65. The most prevalent form of the illness is Alzheimer’s disease, followed by frontotemporal dementia, a progressive form of brain damage that affects behavior and personality. YOD significantly disrupts couples' daily lives and challenges them to navigate complex medical decisions and plan for an uncertain future with no available cure or meaningful treatment to delay symptom progression.
“Young-onset dementia strikes people while they’re still working, parenting or serving as caregivers for other family members,” says lead author Sarah Bannon, PhD, clinical psychologist and postdoctoral fellow within the Integrated Brain Health Clinical and Research Program in the MGH Department of Psychiatry. “Despite the major life disruptions that accompany YOD, there are very few age-appropriate resources available for couples to participate in together. Our work shows the potential to develop resources that actively involve both partners and teach them skills to increase positive communication and mutual problem-solving. Our long-term goal is to develop a program delivered early after diagnosis that helps couples collaboratively plan for the future and preserve their relationship strengths and quality of life.”
The research team interviewed 23 couples recruited from MGH Department of Neurology clinics and social media support groups for YOD. This study is the first to identify coping patterns of couples living with a YOD diagnosis, which will help inform couples-based treatments for YOD. “We looked at both positive and negative ways that couples coped with the challenges they faced after symptom onset. We noticed that many couples mutually avoided discussing their individual thoughts and feelings with each other in the weeks and months early after diagnosis,” explains Bannon, a couples and family psychologist. “That avoidance was understandable, but frequently led to an accumulation of frustration and negative communication between partners over time. Our research found that couples who were better adjusted were able to use positive coping strategies such including viewing YOD as a ‘we-illness,’ involving a teamwork approach. The model we conceptualized can directly inform resources for both partners and can be tailored to meet the unique needs and challenges of each couple.”
Findings emphasize the importance of teaching partners skills to manage their emotions in order to have more open, frequent and explicit communication about difficult topics. “Our study suggested that when partners openly communicate about their challenging or painful emotions, they could work to understand each other’s perspectives,” says senior author Ana Maria Vranceanu, PhD, director of the MGH Integrated Brain Health Clinical and Research Program. “That mutual understanding was critical for couples maintaining their close relationship and adjusting to the ‘new normal’ as a team.”
“Teaching skills to both partners early, while the person living with YOD can still participate, may help both partners manage their own difficult emotions produced by the many stressors and life changes that accompany YOD,” Vranceanu adds. “It can also enable partners to better plan for their future time together and focus on meaningful activities and creative ways of staying connected.”
Bannon is a clinical psychology fellow in the Department of Psychiatry at MGH and at Harvard Medical School (HMS). Vranceanu is founder of the Integrated Brain Health Clinical and Research Program at MGH and associate professor of Psychology at HMS. Co-author Bradford Dickerson, MD, is director of the MGH Frontotemporal Disorders Unit, chair of Progressive Aphasia Research and professor of Neurology at HMS.
The study was supported by the National Institute of Aging and the National Institute of Nursing Research.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Jul | 8 | 2021
La terapia génica con "dedos de cinc" puede ayudar a tratar la enfermedad de Alzheimer, según un estudio en animales
Los investigadores han utilizado una estrategia de ingeniería genética para reducir drásticamente los niveles de tau—una proteína clave que se acumula y se enreda en el cerebro durante el desarrollo de la enfermedad de Alzheimer—en un modelo animal de la enfermedad.
- Press Release
- Jul | 6 | 2021
There is no clinical evidence that the monoclonal antibody aducanumab is beneficial to patients with cerebral amyloid angiopathy, according to officers with the International Cerebral Amyloid Angiopathy Association.
- Press Release
- May | 19 | 2021
A key protein must be cut to create amyloid beta. Groundbreaking work identifies the “lipid raft” in nerve cells where this process occurs, which could offer new targets for drug therapy.
- Press Release
- May | 12 | 2021
During the development and progression of Alzheimer’s disease, a protein called tau accumulates and spreads in the brain. Understanding the mechanisms behind tau spread—and its consequences—may point to new prevention and treatment strategies for Alzheimer’s disease and other forms of dementia.
- Press Release
- Apr | 2 | 2021
These gene variants could suggest new targets for drug development aimed at enhancing neuroplasticity and the stability of synapses.